ECRI teams with value-analysis group on medical equip decisions

ECRI Institute is banding with the Association of Healthcare Value Analysis Professionals (AHVAP) to help hospitals make better decisions around selecting medical equipment.

The care-improvement nonprofit based in Plymouth Meeting, Pa., announced April 26 that the two will collaborate to facilitate the work of hospitals’ value-analysis teams, which review clinical products, equipment and technologies to evaluate their clinical efficacy, safety and impact on organizational resources.

ECRI said the collaboration will generate co-sponsored educational events, quarterly newsletters and white papers to help AHVAP members make decisions informed by evidence of quality and clinical performance.

Barbara Strain, director of supply chain analytics at the University of Virginia Health System in Charlottesville and president of AHVAP’s board of directors, said her group will look to ECRI not only for educational and technical expertise but also for new, customized programs and publications highlighting the value-analysis profession.

On its website, AHVAP describes itself as an organization of nurses, clinical and service professionals whose expertise “bridges the gap between clinical staff and the supply chain process.” The organization has administrative offices in St. Paul, Minn.
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.